The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity

[1]  P. Leeson,et al.  The Role of Neuropeptide Y in Cardiovascular Health and Disease , 2018, Front. Physiol..

[2]  P. Carmichael,et al.  Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway. , 2018, Toxicology in vitro : an international journal published in association with BIBRA.

[3]  N. Güler,et al.  Role of sympathetic cotransmitter galanin on autonomic balance in heart failure: an active player or a bystander? , 2017, Anatolian journal of cardiology.

[4]  L. Vähätalo,et al.  The metabolic syndrome in mice overexpressing neuropeptide Y in noradrenergic neurons. , 2017, The Journal of endocrinology.

[5]  Xuehua Xu,et al.  NPY Impairs Cell Viability and Mitochondrial Membrane Potential Through Ca2+ and p38 Signaling Pathways in Neonatal Rat Cardiomyocytes , 2017, Journal of cardiovascular pharmacology.

[6]  P. Kruzliak,et al.  Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy , 2017, Molecular and Cellular Biochemistry.

[7]  E. Hirsch,et al.  New signal transduction paradigms in anthracycline-induced cardiotoxicity. , 2016, Biochimica et biophysica acta.

[8]  M. Söderström,et al.  Intramyocardial injection of SERCA2a‐expressing lentivirus improves myocardial function in doxorubicin‐induced heart failure , 2016, The journal of gene medicine.

[9]  A. Varró,et al.  Role of the dysfunctional ryanodine receptor - Na(+)-Ca(2+)exchanger axis in progression of cardiovascular diseases: What we can learn from pharmacological studies? , 2016, European journal of pharmacology.

[10]  L. Vähätalo,et al.  Neuropeptide Y in noradrenergic neurons induces obesity in transgenic mouse models , 2016, Neuropeptides.

[11]  E. Jackson,et al.  NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4. , 2015, American journal of physiology. Heart and circulatory physiology.

[12]  Chi Wang,et al.  Loss of Multidrug Resistance–Associated Protein 1 Potentiates Chronic Doxorubicin-Induced Cardiac Dysfunction in Mice , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[13]  Wei Guo,et al.  Neuropeptide Y damages the integrity of mitochondrial structure and disrupts energy metabolism in cultured neonatal rat cardiomyocytes , 2015, Peptides.

[14]  F. Müller,et al.  Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy. , 2015, American journal of translational research.

[15]  J. Määttä,et al.  Neuropeptide Y in the noradrenergic neurones induces obesity and inhibits sympathetic tone in mice , 2015, Acta physiologica.

[16]  R. Carvalho,et al.  Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry Original Paper Acute Doxorubicin-induced Cardiotoxicity Is Associated with Matrix Metalloproteinase-2 Alterations in Rats Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry , 2022 .

[17]  E. Kranias,et al.  Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend. , 2014, Journal of molecular and cellular cardiology.

[18]  N. Herring.  Autonomic control of the heart: going beyond the classical neurotransmitters , 2014, Experimental physiology.

[19]  S. Rabkin,et al.  Role of neuropeptides in cardiomyopathies , 2014, Peptides.

[20]  Amy D. Hanna,et al.  Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A , 2014, Molecular Pharmacology.

[21]  Peixiang Wang,et al.  Erythropoietin modulates imbalance of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in doxorubicin-induced cardiotoxicity. , 2014, Heart, lung & circulation.

[22]  C. Coppola,et al.  Ranolazine protects from doxorubicin‐induced oxidative stress and cardiac dysfunction , 2014, European journal of heart failure.

[23]  Sufang Li,et al.  [Protein interacting with kinase Cα mediates the down-regulation of myocardial norepinephrine transporter expression in mice with adriamycin-induced congestive heart failure]. , 2014, Zhonghua xin xue guan bing za zhi.

[24]  M. Volpe,et al.  Natriuretic peptides in cardiovascular diseases: current use and perspectives. , 2014, European heart journal.

[25]  N. Herring,et al.  Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  F. Sellke,et al.  Local infiltration of neuropeptide Y as a potential therapeutic agent against apoptosis and fibrosis in a swine model of hypercholesterolemia and chronic myocardial ischemia. , 2013, European journal of pharmacology.

[27]  C. Jiang,et al.  Neuropeptide Y induces secretion of high-mobility group box 1 protein in mouse macrophage via PKC/ERK dependent pathway , 2013, Journal of Neuroimmunology.

[28]  Yan Liu,et al.  Role of neuropeptide Y and peroxisome proliferator-activated receptor γ coactivator-1α in stress cardiomyopathy , 2012, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[29]  U. Pesonen,et al.  Neuropeptide Y in the noradrenergic neurons induces the development of cardiometabolic diseases in a transgenic mouse model , 2012, Indian journal of endocrinology and metabolism.

[30]  H. Crijns,et al.  Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. , 2012, Journal of molecular and cellular cardiology.

[31]  Ruiyan Zhang,et al.  Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  Sawa Kostin,et al.  Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. , 2011, International journal of cardiology.

[33]  G. Giridharan,et al.  Bovine Model of Doxorubicin-Induced Cardiomyopathy , 2010, Journal of biomedicine & biotechnology.

[34]  Ruiyan Zhang,et al.  Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. , 2010, European journal of pharmacology.

[35]  Norman Honbo,et al.  Doxorubicin Cardiomyopathy , 2009, Cardiology.

[36]  M. Koulu,et al.  Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury , 2009, Peptides.

[37]  R. Hajjar,et al.  Rescue of Ca2+ overload-induced left ventricular dysfunction by targeted ablation of phospholamban. , 2009, American journal of physiology. Heart and circulatory physiology.

[38]  M. Koulu,et al.  Transgenic Mice Overexpressing Neuropeptide Y in Noradrenergic Neurons , 2008, Diabetes.

[39]  B. McDermott,et al.  NPY and cardiac diseases. , 2007, Current topics in medicinal chemistry.

[40]  D. Jacques,et al.  Neuropeptide Y (NPY) and NPY receptors in the cardiovascular system: implication in the regulation of intracellular calcium. , 2007, Canadian journal of physiology and pharmacology.

[41]  D. Jacques,et al.  NPY regulates human endocardial endothelial cell function , 2007, Peptides.

[42]  A. Dogan,et al.  Protective effects of carvedilol against anthracycline-induced cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[43]  A. Weyman,et al.  Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. , 2006, European heart journal.

[44]  W. Chan,et al.  Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin , 2006, Circulation.

[45]  W. Liang,et al.  Neuropeptide Y induces cardiomyocyte hypertrophy via calcineurin signaling in rats , 2005, Regulatory Peptides.

[46]  E. Olson.  A decade of discoveries in cardiac biology , 2004, Nature Medicine.

[47]  J. Chrast,et al.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. , 2004, The Journal of clinical investigation.

[48]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[49]  R. Quaife,et al.  Coordinate Changes in Myosin Heavy Chain Isoform Gene Expression Are Selectively Associated With Alterations in Dilated Cardiomyopathy Phenotype , 2002, Molecular medicine.

[50]  B. McDermott,et al.  Induction of Hypertrophic Responsiveness of Cardiomyocytes to Neuropeptide Y in Response to Pressure Overload , 2002, Journal of Pharmacology and Experimental Therapeutics.

[51]  R. Olson,et al.  Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. , 2002, Biochemical and biophysical research communications.

[52]  A. Saraste,et al.  Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. , 2000, Cancer research.

[53]  R. Boucek,et al.  Persistent effects of doxorubicin on cardiac gene expression. , 1999, Journal of molecular and cellular cardiology.

[54]  K. Mikoshiba,et al.  Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. , 1995, Circulation.

[55]  X. J. Zhou,et al.  Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes. , 1994, The American journal of physiology.

[56]  P. Singal,et al.  Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. , 1991, The American journal of physiology.

[57]  A. Sollevi,et al.  Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. , 1990, Cardiovascular research.

[58]  C. Wahlestedt,et al.  Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers , 1984, Regulatory Peptides.

[59]  J. M. Kumar,et al.  Baicalein alleviates doxorubicin-induced cardiotoxicity via suppression of myocardial oxidative stress and apoptosis in mice. , 2016, Life sciences.

[60]  F. Waagstein,et al.  The Role of β-Blockers in the Treatment of Cardiomyopathy and Ischaemic Heart Failure , 2012, Drugs.

[61]  G. Vassort,et al.  Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. , 2005, Journal of molecular and cellular cardiology.

[62]  M. Horký,et al.  Molecular biology of doxorubicin-induced cardiomyopathy. , 2002, Experimental and clinical cardiology.